Uceris Tablets

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 11/2/2021
Uceris Tablets Side Effects Center

What Are Uceris Tablets?

Uceris (budesonide) extended release tablets are a corticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.

What Are Side Effects of Uceris Tablets?

Common side effects of Uceris include:

  • headache,
  • nausea,
  • decreased blood cortisol,
  • abdominal pain,
  • fatigue,
  • gas,
  • bloating,
  • acne,
  • urinary tract infection,
  • joint pain,
  • constipation,
  • mood changes,
  • sleep problems (insomnia),
  • excess hair growth,
  • stretch marks, and
  • flushing.

Dosage for Uceris Tablets

The recommended dosage for the induction of remission in adult patients with active, mild to moderate ulcerative colitis is 9 mg Uceris taken orally once daily in the morning with or without food for up to 8 weeks.

What Drugs, Substances, or Supplements Interact with Uceris Tablets?

Uceris may interact with ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, grapefruit or grapefruit juice, proton pump inhibitors (PPIs), H2-blockers, and antacids. Tell your doctor all medications and supplements you use.

Uceris Tablets During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Uceris; it is unknown if it would affect a fetus. Uceris passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Uceris (budesonide) extended release tablets Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Inflammatory Bowel Disease (IBD) Causes, Symptoms, Treatment See Slideshow
Uceris Tablets Consumer Information

1 pharmacies near 20147 have coupons for Entocort EC (Brand Names:Uceris for 2ML of 0.25MG/2ML)

Wegmans Food Markets Inc
Wegmans Food Markets Inc

Est. Regular Price


with free coupon

View Coupon

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • thinning skin, easy bruising, increased acne or facial hair;
  • swelling in your ankles;
  • weakness, tiredness, or a light-headed feeling, like you might pass out;
  • nausea, vomiting, rectal bleeding;
  • pain or burning when you urinate;
  • menstrual problems (in women), impotence or loss of interest in sex (in men); or
  • signs of too much steroid medicine in your blood--acne, bruising, thinning skin, increased facial or body hair, stretch marks, increased body fat, or changes in the shape or location of body fat (especially in your face, neck, back, and waist).

Common side effects may include:

  • headache, dizziness;
  • indigestion, nausea, vomiting, stomach pain, bloating, gas, constipation;
  • feeling tired;
  • back pain, joint pain;
  • painful urination;
  • cold symptoms such as stuffy nose, sneezing, sore throat;
  • pain anywhere in your body; or
  • signs of too much steroid medicine in your blood.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Uceris Tablets (Budesonide Tablets)


Ulcerative colitis affects the colon. The colon is also referred to as the... See Answer
Uceris Tablets Professional Information


Systemic glucocorticosteroid use may result in the following:

  • Hypercorticism and Adrenal Suppression [See WARNINGS AND PRECAUTIONS]
  • Symptoms of steroid withdrawal in those patients transferring from Systemic Glucocorticosteroid Therapy [See WARNINGS AND PRECAUTIONS]
  • Immunosuppression [See WARNINGS AND PRECAUTIONS]
  • Increased Systemic Glucocorticosteroid Susceptibility [See WARNINGS AND PRECAUTIONS]
  • Other Glucocorticosteroid Effects [See WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of UCERIS has been evaluated in controlled and open-label clinical trials which enrolled a combined total of 1,105 patients with ulcerative colitis.

In two 8-week, placebo-controlled studies in patients with active disease (Study 1 and Study 2), a total of 255 patients received UCERIS 9 mg, 254 patients received UCERIS 6 mg, and 258 patients received placebo. They ranged in age from 18-77 years (mean 43), 56% were male, and 75% were Caucasian. The most common adverse reactions were headache, nausea, decreased blood cortisol, upper abdominal pain, fatigue, flatulence, abdominal distension, acne, urinary tract infection, arthralgia, and constipation. The adverse reactions occurring in 2% or more of patients on therapy with UCERIS 9 mg are summarized in Table 1.

Table 1: Summary of Adverse Reactions in Two Placebo-Controlled Trials Experienced by at Least 2% of the UCERIS 9 mg Group (Studies 1 and 2)

  UCERIS 9 mg
(N = 255)
n (%)
(N = 254)
n (%)
(N = 258)
n (%)
Headache 29 (11.4) 37 (14.6) 27 (10.5)
Nausea 13 (5.1) 12 (4.7) 11 (4.3)
Decreased Blood Cortisol 11 (4.3) 6 (2.4) 1 (0.4)
Upper Abdominal Pain 10 (3.9) 8 (3.1) 5 (1.9)
Fatigue 8 (3.1) 5 (2.0) 5 (1.9)
Flatulence 6 (2.4) 8 (3.1) 5 (1.9)
Abdominal Distension 6 (2.4) 4 (1.6) 2 (0.8)
Acne 6 (2.4) 2 (0.8) 5 (1.9)
Urinary Tract Infection 5 (2.0) 1 (0.4) 1 (0.4)
Arthralgia 5 (2.0) 5 (2.0) 4 (1.6)
Constipation 5 (2.0) 1 (0.4) 2 (0.8)

Of UCERIS 9 mg patients, a total of 15% discontinued treatment due to any adverse event (including adverse reactions) compared with 17% in the placebo group.

Table 2 summarizes the percentages of patients reporting glucocorticoid related effects in the 2 placebo-controlled studies.

Table 2: Summary of Glucocorticoid Related Effects in Two Placebo-Controlled Trials (Studies 1 and 2)

  UCERIS 9 mg
(N = 255) n (%)
(N = 254) n (%)
(N = 258) n (%)
Overall 26 (10.2) 19 (7.5) 27 (10.5)
Mood changes 9 (3.5) 10 (3.9) 11 (4.3)
Sleep changes 7 (2.7) 10 (3.9) 12 (4.7)
Insomnia 6 (2.4) 6 (2.4) 8 (3.1)
Acne 6 (2.4) 2 (0.8) 5 (1.9)
Moon face 3 (1.2) 3 (1.2) 4 (1.6)
Fluid retention 2 (0.8) 3 (1.2) 3 (1.2)
Hirsutism 1 (0.4) 0 0
Striae rubrae 0 0 2 (0.8)
Flushing 0 1 (0.4) 3 (1.2)

No clinically significant differences were observed with respect to the overall percentages of patients with any glucocorticoid related effects between UCERIS and placebo after 8 weeks of induction therapy.

Study 3 was an open-label study evaluating UCERIS 9 mg once daily for 8 weeks in 60 patients who had previously completed an 8-week induction study (Study 1), but had not achieved remission. Among patients who took UCERIS 9 mg up to 16 weeks cumulatively across Study 1 and Study 3 combined, similar rates of adverse reactions and glucocorticoid-related effects were seen compared to those who took UCERIS 9 mg for 8 weeks in Study 1.

In Study 4, the safety of long-term treatment with UCERIS 6 mg was evaluated in a placebo-controlled 12-month maintenance study of 123 patients. Patients who had previously completed 8 weeks of therapy in any induction study (Study 1, 2, or 3) and were in remission were randomized to UCERIS 6 mg or placebo once daily for 12 months. In patients who took UCERIS 6 mg for up to 12 months, similar rates of adverse reactions were seen between placebo and UCERIS 6 mg. After up to 12 months of study treatment, 77% (27/35) of the patients in the UCERIS 6 mg and 74% (29/39) of the patients in the placebo treatment groups had normal bone density scans.

In Study 4, the glucocorticoid related effects were similar in patients with up to 12 months of therapy with UCERIS 6 mg and placebo (Table 3).

Table 3: Summary of Glucocorticoid Related Effects Over 12-month Treatment (Study 4)

  UCERIS 6 mg
(N = 62)
n (%)
(N = 61)
n (%)
Overall 9 (14.5) 7 (11.5)
Insomnia 4 (6.5) 4 (6.6)
Mood changes 4 (6.5) 2 (3.3)
Moon face 3 (4.8) 3 (4.9)
Sleep changes 3 (4.8) 3 (4.9)
Acne 3 (4.8) 0
Hirsutism 3 (4.8) 0
Flushing 1 (1.6) 1 (1.6)
Fluid retention 1 (1.6) 1 (1.6)

Postmarketing Experience

In addition to adverse events reported from clinical trials, the following adverse reactions have been identified during postapproval use of oral budesonide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting or causal connection to UCERIS, or a combination of these factors.

Gastrointestinal Disorders: diarrhea, rectal bleeding

General Disorders and Administrative Site Conditions: peripheral edema

Immune System Disorders: anaphylactic reactions

Musculoskeletal and Connective Tissue Disorders: muscle cramps/spasms

Nervous System Disorders: benign intracranial hypertension, dizziness

Psychiatric Disorders: mood swings

Skin and Subcutaneous Tissue Disorders: rash

Vascular Disorders: increased blood pressure

Read the entire FDA prescribing information for Uceris Tablets (Budesonide Tablets)

© Uceris Tablets Patient Information is supplied by Cerner Multum, Inc. and Uceris Tablets Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors